Skip to main content

Table 4 Effect of sex, age and period of diagnosis on mortality risk in the subgroups of metabolic diseases

From: Survival of patients with rare diseases: a population-based study in Tuscany (Italy)

 

Sex

Age at diagnosis

Period of diagnosis

HRb

95% CI

HRc

95% CI

HRd

95% CI

Metabolic diseases

      

Disorders of mitochondrial metabolism

3.12

0.99–9.80

1.05

1.02–1.09

0.67

0.20–2.25

Lysosomal storage diseases

1.21

0.56–2.61

0.99

0.96–1.01

1.04

0.39–2.79

Disorders of vitamin and non-protein cofactor absorption and transport

5.87

0.96–35.98

1.05

1.00–1.11

0.17

0.02–1.54

Disorders of metal metabolism and transport

3.14

0.96–10.30

1.09

1.03–1.15

0.87

0.31–2.43

Disorders of protein metabolism and transport

0.72

0.049–1.04

1.05

1.04–1.07

0.96

0.61–1.50

Other metabolic diseasesa

2.04

0.81–1.17

1.04

1.03–1.07

0.70

0.26–0.94

  1. aGroup of metabolic diseases not attributable to the others listed in the table. Females were the reference group in the analysis by sex; the 2000–2009 period was the reference group and was compared to 2010–2018 period. HR hazard ratio; 95% CI 95% confidence interval
  2. bHRs were adjusted for age and period of diagnosis
  3. cHRs were adjusted for sex and period of diagnosis
  4. dHRs were adjusted for sex and age at diagnosis. Statistically significant differences are reported in bold